Related Experiment Video
Updated: Sep 19, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Lysosomal membrane permeabilization enhances the anticancer effects of POLR1 (RNA polymerase I) transcription
Lucille Ferret1,2,3, Jonathan G Pol1,2, Allan Sauvat1,2
1Centre de Recherche des Cordeliers, Inserm UMRS 1138, Sorbonne Université, Université de Paris Cité, Équipe labellisée par la Ligue contre le Cancer, Institut Universitaire de France, Paris, France.
Abstract:
Lysosomes contribute to the development of drug resistance through various mechanisms that include drug sequestration and the activation of adaptive stress pathways. While inhibitors of DNA-to-RNA transcription exhibit potent anticancer effects, the role of lysosomes in modulating responses to such transcription inhibitors remains largely unexplored. This study investigates this aspect in the context of two potent POLR1 (RNA polymerase I) transcription inhibitors, CX-3543 (quarfloxin) and CX-5461 (pidnarulex). Unexpectedly, CX-3543 was found to accumulate within lysosomes, leading to lysosomal membrane permeabilization (LMP) and the subsequent activation of cellular stress adaptation pathways, including those regulated by the transcription factor TFEB and autophagy. Disrupting TFEB or autophagy increased cell sensitivity to CX-3543, highlighting the cytoprotective role of these processes in counteracting CX-3543-induced cell death. Moreover, targeting lysosomal membranes with chloroquine derivatives or blue light exposure induced substantial LMP, releasing compound CX-3543 from lysosomes. This effect enhanced both the inhibition of DNA-to-RNA transcription and CX-3543-induced cell death. Similar effects were observed when chloroquine derivatives were combined with CX-5461. Additionally, combining CX-3543 with the chloroquine derivative DC661 more effectively reduced the fibrosarcoma growth in immunocompetent mice than either agent alone. Altogether, our results reveal an unanticipated lysosome-related mechanism that contributes to cancer cell resistance to POLR1 inhibitors and propose a strategy to overcome this resistance.Abbreviations: ATG7: autophagy related 7; ATG13: autophagy related 13; Baf A1: bafilomycin A1; CTSB: cathepsin B; DKO: double knockout; G4: Guanine quadruplex; KO: knockout; LAMP1: lysosomal associated membrane protein 1; LAMP2: lysosomal associated membrane protein 2; LGALS3: galectin 3; MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta; MTORC1: mechanistic target of rapamycin kinase complex 1; NCL: nucleolin; POLR1: RNA polymerase I; SQSTM1/p62: sequestosome 1; TFEB: transcription factor EB; TFE3: transcription factor E3; ULK1: unc-51 like autophagy activating kinase 1.
Insights
Lysosomes can cause resistance to cancer drugs like CX-3543 by sequestering them. Targeting lysosomes with chloroquine or light releases the drug, enhancing its cancer-killing effects and reducing tumor growth.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Lysosomes contribute to drug resistance via sequestration and stress pathway activation.
- The role of lysosomes in resistance to transcription inhibitors is largely unknown.
- This study focuses on RNA polymerase I (POLR1) inhibitors CX-3543 and CX-5461.
Purpose of the Study:
- To investigate the role of lysosomes in cellular responses to POLR1 inhibitors.
- To explore mechanisms of drug resistance and potential strategies to overcome it.
Main Methods:
- Investigated drug accumulation and lysosomal membrane permeabilization (LMP) of CX-3543.
- Assessed the impact of TFEB and autophagy pathways on CX-3543 sensitivity.
- Utilized chloroquine derivatives and blue light to induce LMP and drug release.
- Evaluated combination therapies in vitro and in vivo (fibrosarcoma mouse model).
Main Results:
- CX-3543 unexpectedly accumulated in lysosomes, causing LMP and activating TFEB and autophagy.
- Disrupting TFEB or autophagy increased sensitivity to CX-3543, indicating a cytoprotective role.
- Targeting lysosomal membranes enhanced CX-3543's anti-transcription and cell death effects.
- Combination therapy (CX-3543 + DC661) reduced fibrosarcoma growth more effectively than single agents.
Conclusions:
- Lysosomes play an unexpected role in resistance to POLR1 inhibitors.
- TFEB and autophagy pathways confer cytoprotection against CX-3543.
- Targeting lysosomal membranes is a viable strategy to overcome resistance to POLR1 inhibitors.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Intrinsic Apoptotic Pathway

